Global B2B Pharmaceutical Sourcing · Dossier Licensing · Named-Patient Access
💬 WhatsApp · Sign in · Register

EU Critical Medicines Act: What It Means for API and Generic Suppliers

Mitul Agarwal
Written by Mitul Agarwal · B.Pharm, MBA
Founder & Head of Business Development · 25+ years in international pharmaceutical BD&L
Published 21 November 2026
EU Critical Medicines Act: What It Means for API and Generic Suppliers

By the PharmaTradz BD Team. Published November 2026.

In short: The EU Critical Medicines Act will make public tenders for critical medicines reward supply security, not just the lowest price. For vulnerable medicines, at least half of tendered volume can be reserved for EU-made products, or EU manufacturing can be weighted in scoring. Non-EU API and generic suppliers will not be shut out, but they will need to prove resilience and plan their EU footprint now.

For two decades, European hospital and national tenders for off-patent medicines have been won mainly on price. That model delivered cheap antibiotics, anaesthetics and oncology generics, and it also concentrated production in a handful of sites and countries. When a site failed, Europe found out how thin its supply really was. The Critical Medicines Act is the EU's answer, and it changes what a winning bid looks like.

Where the law stands

The Council and the European Parliament reached a provisional political agreement on 12 May 2026, which the European Medicines Agency welcomed the same day. Formal adoption and publication in the Official Journal still have to follow. Once the law is in force, legal analysts expect Member States to set up national programmes within about 12 months and the Commission to publish procurement guidelines within about six months (Simmons & Simmons). The final text may still differ in detail from the May deal, so treat the points below as the direction of travel.

What the Act actually does

  • A Union list of critical medicines. More than 200 active substances will be covered, according to the EMA. These are mostly older, essential medicines where a shortage would harm patients.
  • Vulnerability checks. The EMA's Medicines Shortages Steering Group will assess which of those medicines depend on very few countries or sites for their supply.
  • Resilience in every covered tender. Public tenders for covered medicines must include at least one resilience requirement, such as diversified API sources, buffer stock or proven delivery reliability, not price alone.
  • A preference for EU manufacturing where supply is most fragile. For medicines judged vulnerable, at least half of the volume can be reserved for bidders manufacturing in the EU, or EU manufacturing can be weighted in the score, for at least five years. Exceptions exist for single-supplier markets, failed tenders, disproportionate cost and emergencies.
  • More joint buying. Three or more Member States can ask the Commission to help run a cross-border tender, and five or more can have the Commission buy on their behalf with binding minimum quantities.
  • Support for strategic projects. New or expanded EU manufacturing of critical medicines and their ingredients can gain faster permits and access to funding.

What it means for non-EU API and generic manufacturers

The headline sounds like "buy European", but the detail is more nuanced. Half the volume of vulnerable medicines can still be won by non-EU manufacturers, and medicines that are critical but not judged vulnerable mainly face the resilience requirement, not the EU-production preference. What disappears is the ability to win on price alone.

  • Document your supply chain. Bidders will have to show where production takes place. Expect questions about the API source, the key starting materials behind it and backup sites.
  • Dual sourcing becomes a selling point. A finished-dose maker that has qualified two API sources in different regions will score better than one that depends on a single supplier. That is also an opportunity for API manufacturers outside the dominant supplier countries.
  • Buffer stock costs money. Holding several months of stock for European customers ties up working capital. Price it into bids rather than absorbing it.
  • Partnerships with EU sites gain value. Contract manufacturing, packaging or final release in the EU may help a bid where EU manufacturing is weighted. How "manufactured in the EU" will be defined in each step of the process is one of the most important details still to watch.

What it means for distributors and buyers

European distributors and hospital pharmacies will see tender documents get longer and prices for some critical generics rise modestly. Buyers outside Europe should watch for a different effect: if European tenders lock in volumes and buffer stocks from the most reliable producers, spare capacity for other markets may tighten for the same molecules. Importers in the Middle East, Africa and Asia that rely on spot purchases of older injectables and antibiotics should consider longer-term supply agreements.

Our view

We think the Critical Medicines Act is good policy that will be slower and less disruptive than the headlines suggest. Building new API and sterile capacity in Europe takes years, and Member States will use the exceptions for cost and single-supplier markets often. In the near term the biggest change is cultural: procurement teams will start asking about resilience as a matter of routine, and suppliers who can answer with evidence will win more often, wherever they are based.

The winners will be manufacturers that combine competitive cost with transparent, diversified supply: two API sources, a known starting-material route, a clean inspection record and the ability to hold stock. The losers will be low-price bidders whose entire chain runs through one site. Non-EU suppliers should not wait for the final guidelines; the questions European buyers will ask are already clear.

Practical steps for the next six months

  1. Check whether your products appear on the EU's critical medicines lists.
  2. Map your supply chain down to the key starting materials and identify single points of failure.
  3. Qualify a second API source or site for your most important European products.
  4. Talk to European customers about buffer stock and longer contracts before tenders are rewritten.
  5. If you are an API maker outside the dominant supplier countries, approach EU finished-dose manufacturers now: they will need you.

Related reading on PharmaTradz

The bottom line

Europe is moving from "cheapest wins" to "reliable wins". For suppliers anywhere in the world, the best response is to make resilience visible and provable before the new tender rules arrive.

This article is general business information, not legal advice. The final text of the Act and national rules may differ; check the current position with the relevant authority or a qualified adviser.


Frequently Asked Questions(FAQs)

What is the EU Critical Medicines Act?

An EU law, provisionally agreed in May 2026, to improve the supply security of critical medicines. It adds resilience requirements to public tenders, can favour EU manufacturing for vulnerable medicines, expands joint procurement and supports new EU production.

Does the Act ban non-EU suppliers from EU tenders?

No. For vulnerable medicines, up to half of the volume can be reserved for EU manufacturing, or EU production can be weighted in scoring. The rest stays open, and other critical medicines mainly face resilience criteria.

What counts as a resilience requirement in a tender?

Examples include diversified API sources, buffer stock, proven delivery reliability and transparency about where production takes place. Each covered tender must include at least one such requirement.

When will the new tender rules apply?

After formal adoption and entry into force. Analysts expect Commission guidelines within about six months and national programmes within about 12 months of entry into force.

How should an API manufacturer outside Europe respond?

Map supply down to key starting materials, offer EU finished-dose makers a second qualified source, keep inspection records clean, and be ready to support buffer stock and longer contracts.

Disclaimer: The information presented in this article is for informational and educational purposes only. While every effort has been made to ensure data accuracy and reliability, readers are advised to independently verify all figures, regulations, and market insights before making any business or investment decisions.

Category: Pharma Blogs

← Back to All Articles

 

Subscribe to Our Newsletter

Stay updated on pharma trends and sourcing opportunities.

Please enter the correct answer.
This website uses cookies to ensure you get the best experience. By using our site, you agree to our Privacy Policy.
WhatsApp us